Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF ... and its new drugs look set to bring it to a new growth phase. The firm says it has ...

If a recession does hit, it might also affect the stock market, and different companies and sectors will perform differently.

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

Alyftrek is approved to treat people ages 6 and older who have the genetic condition called cystic fibrosis. Cystic fibrosis happens because of a change in a gene on chromosome 7. This gene is ...

A new 96-week study confirms the long-term safety and sustained efficacy of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis aged 6–11 years.

Cystic fibrosis might sound intimidating ... Inhaled antibiotics help control lung infections, while anti-inflammatory drugs reduce airway swelling. CFTR modulators, the newest class of ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high estimate of $567.00, and a low estimate of $407.00. This upward trend is ...

Dr. Michael Welsh, a longtime University of Iowa physician-scientist, has been named a 2025 recipient of the prestigious ...